Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taste Assessment of BMS-955176 in Healthy Subjects
NCT02608918Phase 1Completed
- Sponsor
- ViiV Healthcare
- Start
- Jan 2016
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BMS-955176 in human immunodeficiency virus infection (HIV), sponsored by ViiV Healthcare. Primary endpoint: Taste properties of HIV Inhibitor up to 2 years. Started Jan 2016; status: completed.
02
Drugs
BMS-955176
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02608918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02608918.